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 2 
ABSTRACT  1 
Fluoroquinolones, which target gyrase and topoisomerase IV, are used for treating 2 
Streptococcus pneumoniae infections. Fluoroquinolone-resistance in this bacterium can 3 
arise via point mutation or interspecific recombination with genetically-related 4 
streptococci. Our previous study on the fitness cost of resistance mutations and 5 
recombinant topoisomerases identified GyrAE85K as a high-cost change. However, this 6 
cost was compensated for by the presence of a recombinant topoisomerase IV (parC + parE 7 
recombinant genes) in strain T14. In this study we purified wild-type and mutant 8 
topoisomerases and compared their enzymatic activities. In strain T14, both gyrase 9 
carrying GyrAE85K and recombinant topoisomerase IV showed lower activities (between 10 
2.0- to 3.7-fold) than the wild-type enzymes. These variations of in vitro activity 11 
corresponded to changes of in vivo supercoiling levels that were analyzed by two-12 
dimensional electrophoresis of an internal plasmid. Strains carrying GyrAE85K and non-13 
recombinant topoisomerasas had lower (11.1% to 14.3%) supercoiling density () values 14 
than the wild-type. Those carrying GyrAE85K and recombinant topoisomerases showed 15 
either partial or total  supercoiling level restoration, with  values 7.9% (recombinant 16 
ParC) and 1.6% (recombinant ParC + recombinant ParE) lower than the wild-type. These 17 
data suggested that changes acquired by interspecific recombination might be selected 18 
because they reduce the fitness cost associated with fluoroquinolone-resistance mutations. 19 
An increase of fluoroquinolone resistance, even in the absence of further antibiotic 20 




In spite of the development of vaccines and chemotherapy, Streptococcus pneumoniae 2 
continues to be an main human pathogen, due in part to its high rate of resistance to antibiotics 3 
and in part to the low coverage and partial inefficiency of available vaccines. The World Health 4 
Organization estimates that about one million children aged <5 years die annually of 5 
pneumococcal pneumonia, meningitis, and/or sepsis worldwide (65). After the usage of the 6 
pneumococcal 7-valent conjugate vaccine in children, which includes most of the antibiotic-7 
resistant serotypes, the incidence of invasive disease declined in both children and adults, 8 
reflecting herd immunity (34, 64). This was associated with a decline in penicillin resistance rates 9 
in many countries (17, 34, 52). However, emergence of serotypes not included in the vaccine, 10 
especially multiresistant serotype 19A, has been observed (9, 17, 44).  11 
Pneumococcal resistance to -lactams and macrolides has spread worldwide in the last 12 
three decades (27). Currently new respiratory fluoroquinolones, which target DNA gyrase 13 
(gyrase) and DNA topoisomerase IV (topo IV), the essential type II DNA topoisomerases, are 14 
recommended as therapeutic alternatives for treatment of adult patients with community-acquired 15 
pneumonia (38). DNA topoisomerases catalyze the interconversions of different topological 16 
DNA forms and thus solve the topological problems associated with DNA replication, 17 
transcription, and recombination (7). DNA supercoiling is maintained in bacteria homeostatically 18 
by the opposing activities of topoisomerases which relax DNA, and by gyrase, which introduces 19 
negative supercoils. In Escherichia coli, transcription of the DNA topoisomerase I gene increases 20 
when negative supercoiling increases (62), and that of the gyrase genes increases after DNA 21 
relaxation (41-43). Likewise, gyrase up-regulation in response to relaxation has also been 22 
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 4 
observed in Streptomyces and Mycobacterium (60, 63). We have recently described the 1 
transcriptional response to DNA relaxation that affects all S. pneumoniae topoisomerases, 2 
triggering the up-regulation of gyrase and the down-regulation of topoisomerases I and IV (19). 3 
We have showed that the pneumococcal genome is organized in topology-reacting gene clusters 4 
that share particular AT content and codon composition characteristics (19). S. pneumoniae is 5 
part of the commensal flora of the human nasopharinx. However, under specific circumstances, 6 
migrates to other niches (ear, lung, bloodstream, cerebrospinal fluid) causing diverse pathologies. 7 
Since the level of bacterial DNA supercoiling is affected by diverse environmental conditions 8 
(13, 56, 61), and global genome transcription is dependent on the degree of supercoiling (19, 25, 9 
29, 51), changes in DNA topology would be crucial for cell viability and for the infective 10 
capacity of S. pneumoniae on their diverse niches (with diverse environmental conditions) in the 11 
human host. 12 
Gyrase (GyrA2GyrB2) introduces negative supercoils into DNA (23) and topo IV 13 
(ParC2ParE2) acts mainly in chromosome partitioning (31). Fluoroquinolones inhibit these 14 
enzymes by forming a ternary complex of drug, enzyme, and DNA. Cellular processes acting on 15 
this complex would yield to the formation of irreparable double-stranded DNA breaks that cause 16 
bacterial death (14). Genetic and biochemical studies have shown that ciprofloxacin (CIP) and 17 
levofloxacin, target primarily topo IV and secondarily gyrase in S. pneumoniae (18, 28, 45, 48, 18 
59). However, for moxifloxacin, gyrase is the primary target (26).  19 
Fluoroquinolone-resistant clinical isolates carry mutations in the quinolone resistance-20 
determining regions (QRDRs), which are located in the N-terminus of ParC or GyrA and in the 21 
C-terminus of ParE. Although CIP is not an effective antipneumococcal drug, we used it to detect 22 
fluoroquinolone resistance, and considered a CIP-resistance breakpoint MIC ≥4 μg/ml  to 23 
 5 
improve detection of first-step mutant strains (8, 10, 11). Low-level (MIC of 4-8 g/ml) CIP-1 
resistant strains had mutations altering the QRDRs of one of the two subunits of topo IV: S79, 2 
S80 or D83 of ParC (10, 28, 45), D435 of ParE (50). High-level (MICs  16 g/ml) CIP-resistant 3 
strains had additional GyrA changes (S81 or E85) (28, 45).  4 
A study (years 2004-2005) including 15 European countries (54) showed a low level (< 5 
3%) of fluoroquinolone resistance in S. pneumoniae, with the exception of Poland (4.4%), 6 
Finland (6.6%), and Italy (7.2%). Higher rates have been detected in some Asian countries (21), 7 
as well as in Canada (1). In Canada, an increase of CIP resistance between 1998 (0.6%) and 2006 8 
(7.3%) occurred in conjunction with increased consumption (1). In Spain, two epidemiological 9 
studies performed in 2002 (11) and 2006 (10) showed a stable low rate of CIP resistance ( 10 
2.3%), maybe influenced by the stabilization of CIP consumption in this period. However, an 11 
increase in resistance in some European countries in which fluoroquinolone use has increased 12 
(data from European surveillance of antimicrobial consumption, http//www.esac.ua.ac.be) is not 13 
unexpected. 14 
Resistance changes can be acquired either by spontaneous mutation or by intra-specific 15 
(58) or inter-specific recombination with related streptococci of the mitis group (SGM) (5, 11, 20, 16 
58). The fluoroquinolone-resistant pneumococcal recombinant isolates studied by our group have 17 
acquired portions of either parE (unpublished results), parC (11), or parE plus parC (5, 11, 20) 18 
from SMG. In the latter case, given the presence of the ant gene in the intergenic parE-parC 19 
region of SMG, recombinants acquired an extra gene in the recombination process and 20 
consequently, had larger intergenic parE-parC regions (1.1 to 7.2 Kb) than non-recombinant 21 
pneumococci (0.4 Kb). 22 
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 6 
The evolution of antibiotic resistance depends on the balance between antibiotic use and 1 
the fitness cost (typically observed as a reduced growth rate) imposed by resistance mutations (2). 2 
A direct relation between fluoroquinolone consumption and increase in resistance in S. 3 
pneumoniae has been described (8, 36). In addition, fitness depends on the specific drug/ 4 
mutation combination (15, 22, 33, 37), and compensatory mutations have been described that 5 
ameliorate the fitness loss (6). There are a few reports on fitness cost of fluoroquinolone-6 
resistance mutations in S. pneumoniae (4, 24, 30, 55) and only one in which recombinant strains 7 
were considered (4). In our previous study we analyzed a set of 24 CIP-resistant isogenic strains 8 
and categorized the mutations as conferring no-, low-, or high-biological cost to the strains (4). 9 
The mutation causing the GyrAE85K change was identified as a high-cost mutation. However, 10 
the fitness cost imposed by this change was compensated by the presence of a recombinant topo 11 
IV in strain T14. A single study, in which enzymatic activity determinations were not made, has 12 
related fitness cost of quinolone resistance mutations in E. coli gyrase and supercoiling level 13 
measured in mono-dimensional agarose gel electrophoresis (3). In this study we combined high-14 
resolution two-dimensional agarose gel electrophoresis with enzymatic assays to get insight into 15 
the compensation of the fitness cost imposed by GyrAE85K by the presence of a recombinant 16 
topo IV enzyme.  17 
 18 
MATERIALS AND METHODS 19 
Bacterial strains, growth and transformation of bacteria. S. pneumoniae strains used 20 
were wild-type R6 and its isogenic derivatives Tr7, T1, T4, T9 and T14 (4). They were grown in 21 
a casein hydrolysate-based medium with 0.3% sucrose (AGCH) as energy source and 22 
transformed as described previously (35). E. coli was grown in Luria-Bertani (LB) broth and 23 
 7 
transformed as described (57). The pQE1 vector/M15 E. coli host system (Qiagen) was used to 1 
over-express S. pneumoniae GyrB, GyrA, ParC, and ParE proteins in E. coli.  2 
Cloning of topoisomerase genes, protein over-expression and purification. Genes 3 
were amplified from chromosomal DNA of strains R6, T1, T9 or T14. Forward oligonucleotides 4 
were previously phosphorylated and reverse primers contained SphI restriction sites in their 5´-5 
ends (Table 1). Amplifications (50 µl) were performed with 2.5 U of Pfu DNA polymerase 6 
(Fermentas), 0.1 µg of template DNA, 1 µM (each) of oligonucleotide primers, and 0.2 mM 7 
(each) deoxynucleoside triphosphates. PCR reactions included 1 cycle of 5 min denaturation at 8 
94ºC; 30 cycles of 1 min at 94ºC, 1 min at 55 or 45ºC, 3 min polymerase extension step at 72ºC; 9 
a final 5 min extension step at 72ºC and slow cooling at 4ºC. Oligonucleotides were removed 10 
(QIAquick PCR Purification Kit, Qiagen), PCR products were cut with SphI, cloned into plasmid 11 
pQE1 digested with SphI + PvuII, and established into E. coli M15 (pREP4). Transformants 12 
were selected in LB plates containing ampicillin (100µg/ml, for pQE1 selection) and kanamycin 13 
(25 µg/ml, for pREP4 selection). The pQE1 vector/ M15 (pREP4) system permits the controlled 14 
hyperproduction of proteins with an N-terminal Met-Lys-(His)6-Gln- fusion encoded by genes 15 
placed under the control of a phage T5 promoter and two lac operator sequences. Plasmid pREP4 16 
constitutively expresses the LacI repressor. Expression of recombinant proteins cloned into pQE 17 
vectors is induced by isopropyl-β-D-thiogalactoside (IPTG) which binds to LacI and inactivates 18 
it. This inactivation allows the host cell’s RNA polymerase to transcribe the sequences 19 
downstream from the T5 promoter. The various E. coli M15 (pREP4) strains harbored pQE1 20 
recombinant plasmids carrying either parC (from R6, T1, T9 and T14), parE (from R6 and T14), 21 
gyrA (from R6 and T14) or gyrB (from R6) genes. Strains were grown overnight at 37ºC in LB 22 
 8 
medium, diluted 20-fold in 200-ml medium and grown at 37ºC (for GyrB or ParE 1 
overproduction) or at 30ºC (for GyrA or ParC) until OD600 nm = 0.6. At this moment, 1 mM IPTG 2 
was added, and growth was continued for another 30 min. Bacteria were collected by 3 
centrifugation and suspended in 4 ml of 50 mM NaH2PO4, 300 mM NaCl (column buffer) 4 
containing 10 mM imidazole prior to flash freezing in dry ice. The suspension was thawed at 0ºC 5 
and incubated for 30 min with lysozyme (1 mg/ml) and Triton X-100 (0.2%). Cell debris was 6 
removed by centrifugation (10,000 x g for 20 min at 4ºC), and the supernatant mixed with 2 ml of 7 
50% Ni-nitriloacetic acid resin slurry (Qiagen) by slow agitation on a rotary shaker at 4ºC for 1 h. 8 
The mixture was packed in a column and washed with 8 ml of column buffer containing 20 mM 9 
imidazole. His-tagged proteins were eluted with a linear gradient 50-250 mM imidazole in 10 
column buffer. Protein fractions were examined by sodium dodecyl sulfate polyacrylamide gel 11 
electrophoresis (SDS-PAGE), and those containing proteins of the expected size were pooled and 12 
dialyzed overnight at 4ºC against 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.2 mM EDTA, 1 mM 13 
DTT, and 50% glycerol.  14 
Topoisomerase catalytic assays. Gyrase and topo IV were reconstituted by incubation of 15 
their corresponding subunits with an excess of GyrB or ParE subunits (1:3.8 ratio) for 1 h at 4ºC. 16 
Gyrase-mediated supercoiling reactions (100 µl) were performed during 1 h at 37ºC as described 17 
(18) using 0.4 µg of relaxed pBR322 DNA (Inspiralis, Norwich, UK) and reconstituted gyrase. 18 
The reaction was terminated by addition of 7.5 µl of 0.5 M EDTA (1-min incubation), and further 19 
addition of 1% SDS and 50 µg/ml proteinase K (15-min incubation at 37ºC). Samples were 20 
ethanol precipitated, suspended in electrophoresis loading buffer, and analyzed in 1% agarose 21 
gels run at 2 V/cm for 12 h. Topo IV decatenation assays (12 µl) were performed as described 22 
(18) using 0.4 µg of k-DNA from Crithidia fasciculata (Inspiralis, Norwich, UK), and 23 
 9 
reconstituted topo IV. Reaction mixtures were incubated at 37ºC for 1 h and terminated by 1 
addition of 6 µl of loading buffer and 12 µl of H2O. Samples were analyzed by electrophoresis in 2 
0.7% agarose gels run at 3 V/cm for 1 h and then at 7 V/cm for 2 h. Relaxation assays (20 l) 3 
were performed as described (49) using 50 ng of supercoiled pBR322 and 12.5-fold higher 4 
amount than in the decatenation assay of reconstituted topo IV. Samples were analyzed by 5 
electrophoresis in 1.4% agarose gels run at 1.8 V/cm for 22 h. After electrophoresis, gels were 6 
subjected to Southern hybridization using a 506-bp pBR322 probe obtained by amplification of 7 
plasmid DNA with 5’-byotinilated pBR-1 and pBR-2 oligonucleotides (Table 1). Southern blot 8 
and hybridization were performed following the Phototope®-Star kit (New England Biolabs) 9 
instructions. Cleavage assays were carried out either in 40 mM Tris-HCl pH 7.5, 6 mM MgCl2, 10 
10 mM DTT, 200 mM potassium glutamate and 50µg/ml BSA (for topo IV) or in 35 mM Tris-11 
HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM DTT and 0.1 mg/ml BSA (for gyrase). 12 
Reconstituted topoisomerases were incubated with 0.4 µg of supercoiled pBR322 in 25 µl 13 
reaction mixtures in the presence of different concentrations of ciprofloxacin to account for 16  14 
MIC for each strain (for topo IV) or for 100 x MIC (for gyrase). After 30-min incubation at 37ºC, 15 
1 µl of 10% SDS and 2 µl of a 20 mg/ml proteinase K were added, and incubation continued for 16 
30 min at 45ºC. Loading buffer was added to the samples, which were analysed by 17 
electrophoresis in 1% agarose gels, which were run at 2 V/cm for 12 h.. 18 
Two-dimensional agarose gel electrophoresis. Isolation of plasmid DNA from S. 19 
pneumoniae cultures grown on AGCH containing 1g/ml of tetracycline (for selection of pLS1) 20 
was performed using a neutral method to avoid plasmid denaturation. Exponentially growing 21 
cells were harvested and lysed by treatment with lysozyme and a detergent solution of 1% Brij 58 22 
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and 0.4% sodium deoxycholate (40). Plasmid molecules were analyzed in neutral/neutral two-1 
dimensional agarose gels. The first dimension was run in a 0.4% (w/v) agarose (Seakem; FMC 2 
Bioproducts) gel in 1 Tris-borate-EDTA (TBE) buffer containing 1 µg/ml of chloroquine 3 
(Sigma) at 1.5 V/cm at room temperature for 19 h. The second dimension was in 1% agarose gel 4 
in TBE buffer containing 2 g/ml of chloroquine at 7.5 V/cm for 79 h at 4ºC. Chloroquine was 5 
added to the TBE buffer in both the agarose and the running buffer. After electrophoresis, gels 6 
were subjected to Southern hybridization using a 240-bp PCR fragment obtained from pLS1 7 
DNA with 5´-biothinylated pLS1F and pLS1R (Table 1) as a probe on gels transferred to nylon 8 
membranes (Inmobylon NY
+
, Millipore). Chemiluminiscent detection of DNA was performed 9 
with the Phototope®-Star kit (New England Biolabs). Images were captured in a VersaDoc 10 
MP400 system and analyzed with the Quantity One program (BioRad). DNA linking number 11 
(Lk) was analyzed by quantifying the amount of every given topoisomer. DNA supercoiling 12 
density () was calculated with  = Lk /Lk0. Linking number differences (Lk) were 13 
determined with the equation Lk = Lk - Lk0, in which Lk0 = N/10.5, where N is the DNA size in 14 
bp (4408 for pLS1) and 10.5 the number of bp per one complete turn in B-DNA, the most 15 
probable helical repeat of DNA under the conditions used. 16 
 17 
RESULTS 18 
Mutant DNA topoisomerases are less active than wild type enzymes. Five strains 19 
(Figure 1A), which carry various fluoroquinolone-resistance mutations and parE-parC structures, 20 
were selected for this study among a series of isogenic R6-derived strains previously constructed 21 
(4). While strain T1, which was used as a control, carried ParCS79F as a single change, the 22 
 11 
remaining four strains carried GyrAE85K: one as a single change (Tr7); three (T4, T9, and T14) 1 
in combination with ParCS79F. Of these last strains, while T4 carried a non-recombinant parC 2 
gene, T9 carried a recombinant parC, and T14 carried both parE and parC recombinant genes, 3 
and, accordingly, the ant gene in its intergenic region. Consequently, T9 and T14 carried 4 
recombinant (rec) topoisomerase subunits that have, in addition to changes involved in 5 
resistance, other changes (Fig. 1A) not involved in resistance (4). Changes present in recParC of 6 
strain T9 were S52G, N91D, A190T, and I201V. Strain T14 had the S52G, N91D changes, and 7 
carried in addition Y23H. The recParE subunit of strain T14 carry the G486S, I493L and F571L 8 
changes not involved in resistance (Fig. 1A). The fitness cost of these strains has been previously 9 
determined in competition experiments with the R6 strain (4). In our previous study, mixed 10 
cultures of R6 and each isogenic resistant strain were incubated in antibiotic-free medium for 6 h 11 
(c.a. 10-12 generations), diluted 1000-fold and re-growth for an additional 6 h period. The 12 
number of viable cells was determined at 0 h, at the end of the first 6 h cycle and after the second 13 
6 h cycle. Strains were classified as high-cost when showed relative mean fitness lower than 1 14 
both in 1-cycle (95% CI= 0.79-0.99) and in 2-cycle of competitive growth (95% CI= 0.63-0.89) 15 
experiments. Low-cost strains showed relative mean fitness lower than 1 only in the 2-cycle 16 
(95% CI= 0.81-0.99) experiments, while in the no-cost strains the 95% CI of the mean relative 17 
fitness includes the 1 value. From this classification, T1 was considered to be a low-cost strain, 18 
and all strains carrying GyrAE85K, except T14 that showed no cost, were classified as high 19 
fitness cost strains. 20 
A series of His-tagged topoisomerase subunits were overexpressed and purified (Fig. 1B) 21 
in order to perform enzymatic assays. All wild-type (wt) subunits were obtained from strain R6, 22 
GyrAE85K from T14, ParC subunits from T1 and T14, and ParE from T14. Most proteins were 23 
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obtained in soluble form with 90% homogeneity. However, additional bands of lower molecular 1 
weight were observed in GyrB and ParE of R6 (Fig. 1B). As shown below, these additional 2 
proteins did not interfere with the topoisomerase enzymatic assays used. The main gyrase 3 
activity, the ability to supercoil relaxed pBR322 in the presence of ATP was assayed. No 4 
supercoiling activity was observed when either the GyrA (Fig. 1C, lines A and AE85K) or 5 
wtGyrB (Figure 1C, line B) subunits alone were assayed. Supercoiling activities were only 6 
observed when both subunits were combined (Fig. 1C, lines A+B and AE85K+B). To achieve 7 
50% of supercoiling activity, 125 fmole and 250 fmole of wtGyrA and GyrAE85K subunits, 8 
respectively, were required (Fig. 2A), showing that the mutant subunit is 2-fold less active than 9 
the wild-type GyrA subunit (Table 2). Two activities were assayed for topo IV: decatenation and 10 
relaxation. Decatenation, which was assayed using k-DNA as a substrate, was observed when the 11 
ParC and ParE subunits were combined (Fig. 1D, lines C+E), while no activity was observed 12 
with either the ParC or ParE (Fig. 1D, lines C and E) subunits alone. The decatenation activities 13 
of topo IV enzymes reconstituted with wtParC (from R6) or ParC mutant subunits (ParCS79F 14 
from T1, and recParCS79F from T14) were compared. ParE subunits assayed were wt (from R6) 15 
and recParE from T14. As shown in Fig. 2, 50% decatenation activity was achieved with 50 16 
fmole (wtParC + wtParE), 100 fmole (ParCS79F + wtParE), 163 fmole (recParCS79F + wtParE) 17 
and 127 fmole (recParCS79F + recParE) (Fig. 2B and 2C). These results showed that ParCS79F 18 
had 2-fold lower activity than wtParC, and that topo IV reconstituted with recParC or recParE + 19 
recParC showed decatenation activities 3.3- and 2.5-fold lower, respectively, than wt topo IV 20 
(Table 2). Relaxation activity for topo IV was about 100-fold lower than that of decatenation, as 21 
it has been previously described (49), for this reason, 50 ng instead 400 ng of supercoiled 22 
 13 
pBR322 were used as a substrate and the reaction products were detected after Southern-blot 1 
hybridization as described in material and methods. Relaxation was observed when the ParC and 2 
ParE subunits were combined (Fig. 1E, lines C+E), while no activity was observed with either the 3 
ParC or ParE (Fig. 1E, lines C and E) subunits alone. The relaxation activities of topo IV 4 
enzymes reconstituted as described above were compared. As shown in Fig. 2, 50% relaxation 5 
activity was achieved with 0.8 pmole (wtParC + wtParE), 1.2 pmole (ParCS79F + wtParE), 1.2 6 
pmole (recParCS79F + wtParE) and 1.6 pmole (recParCS79F + recParE) (Fig. 2C). These results 7 
showed that ParCS79F and recParC had activities 1.5-fold lower than wtParC, and that topo IV 8 
reconstituted with or recParE + recParC showed a relaxation activity 2.0-fold lower than wt topo 9 
IV (Table 2). 10 
Since it has been suggested that fluoroquinolone action it is better assayed by stimulation 11 
of topoisomerase-mediated cleavage, this assay was performed with both gyrase and topo IV in 12 
the presence of an excess (100  MIC and 16  MIC, respectively) of CIP. In these assays, the 13 
enzyme is blocked in a reaction intermediary and renders linear DNA from CCC pBR322 after 14 
treatment with proteinase K and SDS, as described in material and methods. When the activities 15 
of GyrA and GyrB subunits were analyzed, linearization was only observed when the GyrA and 16 
GyrB subunits were combined (Figure 1F, lines A+B), while no activity was observed with either 17 
subunit alone. When this cleavage assay was performed using wtGyrA and GyrAE85K subunits, 18 
a 20% activity was achieved with 289 fmole (wtGyrA + GyrB) and 1035 fmole (GyrAE85K + 19 
GyrB), showing that GyrAE85K had 3.7-fold lower activity than the wt enzyme (Figure 3A). 20 
When the activities of the ParC and ParE subunits of topo IV were analyzed (Fig. 1G), some 21 
linearization was observed when only the E subunit was used, however, this residual activity, 22 
 14 
which is probably due to the contaminating band observed in the purification (Fig. 1B), did not 1 
interfere with the assay. When ParC + ParE subunits were combined, a 3-fold greater activity was 2 
observed when the assay was performed in the presence of ciprofloxacin than in its absence (Fig. 3 
1G). When this cleavage assay was used to test topo IV enzymes, a 50% activity was achieved 4 
with 282 fmole (ParC + wtParE), 848 fmole (ParCS79F + wtParE), 740 fmole (recParCS79F + 5 
wtParE) and 963 fmole (recParCS79F + recParE) (Fig. 3B and 3C). These results showed that 6 
topo IV carrying ParCS79F, recParC, and recParC + recParE had 3.2-, 2.7- and 3.4-fold lower 7 
cleavage activity than the wt enzyme, respectively (Table 2).  8 
DNA topoisomer distribution varied in isogenic strains carrying the GyrAE85K change. To 9 
estimate the supercoiling level in vivo, we analyzed the influence of the parC and gyrA 10 
mutations in the supercoiling level of plasmid pLS1, able to replicate in S. pneumoniae. This 11 
plasmid was introduced into strains R6, Tr7, T1, T4, T9 and T14 and their topoisomer 12 
distribution was analyzed by using two-dimensional agarose gel electrophoresis (Fig. 4A). 13 
Plasmid pLS1 is appropriate to study gyrase activity, given that it replicates by a rolling circle 14 
mechanism (12) and all their genes are transcribed in the same direction, avoiding problems of 15 
transcription interference during replication (47). Topoisomers were distributed in the 16 
autoradiograms in a bubble-shaped arc, negative supercoiled molecules being located to the right 17 
and positive supercoiled ones to the left (Fig. 4A). To calculate the supercoiling density () 18 
values it was considered that the induced ΔLk of monomers by 2 g/ml chloroquine in pLS1 is 19 
−14 (19). No significant difference (6.3%) in supercoiling density () values were observed 20 
between the wtR6 (-0.063) and T1 carrying the ParCS79F change (-0.059). However  values for 21 
strains carrying GyrAE85K, such as Tr7 that carries this single change (-0.054) and T4 that also 22 
 15 
carries ParCS79F (-0.056) were 14.3 and 11.1% lower, respectively, than for R6. These results 1 
suggest that the GyrAE85K change causes a supercoiling level deficiency. However, two 2 
recombinant strains (T9 and T14) that also carry GyrAE85K, showed  values that differ from 3 
the non-recombinant (Tr7 and T4) strains. While T9 (recParC) had a  value (-0.058) 7.9% lower 4 
than R6, T14 (recParC + recParE) had a  value (-0.062) equivalent (1.6% lower) to R6. 5 
Supercoiling densities and mean relative fitness after 12 h of competitive growth showed a good 6 
correlation (r
2
= 0.75, p<0.0001) (Fig. 4B). 7 
 8 
DISCUSSION 9 
Under laboratory conditions, the frequencies of CIP-resistance acquisition either via inter-10 
specific recombination or mutation are about 10
-3 
(27, 30) and 10
-9
 (54), respectively. However, 11 
the prevalence of CIP-resistant S. pneumoniae clinical isolates that have acquired resistance by 12 
interchange with SMG is unexpectedly low, accounting for 3- to 10% of the resistant isolates (5, 13 
12, 63). Even when factors such as DNA availability and competence state of the recipient cells 14 
in the natural environment could affect horizontal transfer, it has been estimated that the ratio of 15 
recombination/ mutation in natural S. pneumoniae populations is 10:1 (17).  16 
The fitness cost imposed by the DNA interchange could explain the low frequency of 17 
fluoroquinolone-resistant recombinant S. pneumoniae clinical isolates. Strain T14 had a parE-18 
ant-parC structure and carries recParE + recParC subunits. Two factors could theoretically affect 19 
the fitness of this recombinant; one is a putative discoordination of the parE-ant-parC operon 20 
transcription, and the other the existence of recombinant topo IV subunits. With respect the first 21 
factor, we have previously shown that transcription of the operon from a promoter located 22 
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 16 
upstream of parE was not affected, neither in T14 nor in other clinical isolates with small (<2 1 
Kb) intergenic regions (4). With respect the second factor, it would be expected that a 2 
recombinant gyrase or topo IV enzyme, which has a tetrameric structure, would be a less efficient 3 
enzyme than a non-recombinant one and would cause fitness cost to the strain that carried it. 4 
However, strain T14 shows a compensation of the fitness cost imposed by the GyrAE85K change 5 
(4) maintaining its chromosome supercoiling level due to the conjunction of suboptimal activities 6 
of its recombinant topo IV and mutant gyrase enzymes. Since the strains analyzed in this study 7 
were isogenic, no alterations in topoisomerase I activity is expected. We showed that the reduced 8 
gyrase activity on supercoiling produces a decrease in bacterial fitness, which is compensated by 9 
a reduced relaxing activity of topo IV. The two effects balance to give a nearly wild type level of 10 
supercoiling and thus, of the bacterial fitness. 11 
Gyrase enzymatic assays showed that the GyrAE85K enzyme has lower activity (Figs 2 12 
and 3, Table 2) than the wt enzyme. As a consequence, the supercoiling level detected in pLS1 of 13 
strains carrying this change is affected in. Although we have not measured the supercoiling level 14 
of the bacterial chromosome, the values obtained on small plasmids provide an good estimation 15 
of chromosomal supercoiling (53). Supercoiling density values for plasmid pLS1 in strains Tr7 16 
and T4, which carry GyrAE85K, were 14.3 and 11.1% lower, respectively than the wt strain (Fig. 17 
4). However, recombinant strain showed a recovery. A full supercoiling level recovery ( value 18 
of -0.062, equivalent to R6) was observed in strain T14 (recParC + recParE), which is in 19 
accordance with the lower activities of its topo IV enzyme. Then, the lower enzymatic activities 20 
of gyrase and topo IV of strain T14 allowed an appropriate supercoiling level in vivo. Likewise, 21 
partial restoration of the supercoiling level ( value 7.9% lower than R6) was observed in T9 22 
 17 
(recParC). Although we do not have purified topo IV of strain T9, it can be assumed that its 1 
activity would be equivalent to that of recParCS79F from T14 and wtParE from R6. Then, the 2 
partial restoration in  values could be due to a lower activity of its topo IV enzyme. 3 
The lower activities of the recombinant topo IV enzymes from T9 and T14 could be 4 
attributed in part to the presence of the ParCS79F change involved in resistance, and in part to the 5 
rest of amino acid changes not involved in resistance. Of their 3.3-fold (T9) and 2.5-fold (T14) 6 
lower activities detected in decatenation assays, only part (about 2-fold) could be attributed to the 7 
ParCS79F change of strain T1. Likewise, of the 2.0-fold lower activity detected in relaxation 8 
assays T14, only part (about 1.5-fold) could be attributed to the ParCS79F change. However, this 9 
correspondence was not total when the cleavage-complex formation activity was considered: 10 
activity decreases for ParCS79F (3.2-fold), recParCS79F (2.7-fold), recParCS79F + recParE 11 
(3.4-fold), with respect to the wtParC do not perfectly fit with the estimated in vivo supercoiling 12 
level. These differences may be due to the in vitro activity conditions that do not necessarily 13 
reflect the in vivo conditions. Nevertheless, a good correlation was observed between  values 14 
and mean relative fitness (Fig. 4B). These results show that the in vivo determinations are more 15 
accurate and sensitive than the enzymatic assays in vitro and suggest that the fitness cost is 16 
related to the level of supercoiling of the plasmid, and presumably, of the chromosome. 17 
In conclusion, the presence of suboptimal topoisomerases, both gyrase that introduces 18 
negative supercoils and topo IV that relaxes DNA, allows the restoration of wild-type 19 
supercoiling levels and bacterial fitness. A similar phenomenon was noticed in E. coli 20 
fluoroquinolone-resistant strains where the addition of a parC resistance mutation to an already 21 
 18 
low-fitness gyrase mutant caused a further reduction in drug susceptibility and an increase in 1 
relative fitness (39). 2 
The variations in the  values of the various strains used in our study were in the 1.6% 3 
(T14) to 14.3% (Tr7) range. These figures are considerably lower than the 23% variation that 4 
triggers a global transcriptional response in S. pneumoniae, which includes up-regulation of 5 
gyrase and down-regulation of relaxing topoisomerases and allows the recovery of the 6 
supercoiling levels (19). To test if an inherent transcriptional response occurred in the strains 7 
used in our study, real-time RT-PCR experiments were performed to detect changes in the 8 
expression of topoisomerase genes. No significant variations (data not shown) were detected, 9 
suggesting that either  variations >14.3% are necessary to trigger the supercoiling homeostatic 10 
response or that real-time RT-PCR is not sensitive enough to detect the predicted low variations 11 
in transcription of the topoisomerase genes. 12 
It is well known that the fitness cost of drug resistance can be reduced by selection of low-13 
cost mutations (4, 30, 55) or by accumulation of secondary fitness-compensating mutations that 14 
do not reduce resistance (32, 46). During evolution, compensatory mutations, that arise 15 
spontaneously, are selected because they provide a competitive advantage. Our data show that 16 
mutations acquired by S. pneumoniae by interspecific recombination might be selected because 17 
they reduce the fitness costs of some fluoroquinolone-resistance mutations. Given the 10:1 18 
prevalence of transformation versus mutation in natural S. pneumoniae populations (16), an 19 
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FIGURE LEGENDS 1 
FIG. 1. Characteristics of the strains used and of their gyrase and topo IV enzymes. (A) Amino 2 
acids that change in strains Tr7, T1, T4, T9 and T14 with respect to R6 are indicated and those 3 
involved in fluoroquinolone resistance are showed in bold-face and underlined. For each strain is 4 
shown their ciprofloxacin (CIP) MIC, mean relative fitness and 95% CI calculated in competition 5 
experiments with R6 (4). Fitness cost categorized as high is shown in bold-face and underlined. 6 
(B) Purified topoisomerase subunits revealed by staining with Coomassie blue. His-tagged 7 
proteins were overexpressed in E. coli, purified by nickel resin chromatography, and examined 8 
on an SDS-12% polyacrylamide gel. Mw, molecular weight marker (sizes in kDa). 9 
Approximately 0.5 µg of each protein was loaded per well. (C) Supercoiling activity of gyrase 10 
subunits. Reactions contained no enzyme (lane 0), 142.5 fmol of GyrA (lane A) or GyrAE85K 11 
(lane AE85K), 541.5 fmol of GyrB (lane B) or reconstituted wild type (lane A+B) and mutant 12 
(lane E85K+B) gyrase. N, nicked; R, relaxed; S, negatively supercoiled pBR322. (D) 13 
Decatenation activity of topo IV. Standard reaction mixtures containing either no enzyme (lane 14 
0), 16 fmol of ParC (lane C), 61 fmol of ParE (lane E), or reconstituted topo IV (lane C+E). 15 
kDNA, concatenated kinetoplast DNA; m, monomers. (E) Relaxation activity of topo IV. 16 
Standard reaction mixtures containing either no enzyme (lane 0), 2.5 pmol of ParC (lane C), 9.3 17 
pmol of ParE (lane E), or reconstituted topo IV (lane C+E). (F) Stimulation of gyrase-mediated 18 
cleavage activity by ciprofloxacin. Reactions contained either no enzyme (lanes 0), 1.1 pmol of 19 
GyrA (lane A), 5.9 pmol of GyrB (lane B) or reconstituted gyrase (lanes A+B). (G) Stimulation 20 
of topo IV-mediated cleavage activity by ciprofloxacin. Reactions contained either no enzyme 21 
(lanes 0), 2.3 pmol of ParC (lane C), 8.7 pmol of ParE (lane E) or reconstituted topo IV (lanes 22 
 30 
C+E). The different forms of plasmid pBR322 are indicated: OC, open circle; L, linear; S, 1 
negatively supercoiled. 2 
FIG. 2. The supercoiling and decatenation activities of mutant topoisomerases are lower than 3 
those of wild-type enzyme. (A) Gyrase supercoiling. Subunits wtGyrA or GyrAE85K (lane 4 
AE85K) were reconstituted with wtGyrB in a 1:3.8 proportion and used to supercoil relaxed 5 
plasmid pBR322 (0.4 g) with various amounts of reconstituted gyrase (31 to 500 GyrA fmol). 6 
Lane 0, relaxed pBR322 sustrate. (B) Decatenation activity of topo IV (lanes E+C) and its 7 
ParCS79F mutant (lanes E+CS79F) reconstituted with wtParE, recParC (lanes E+C*S79F) or in 8 
recParE+recParC (lanes E*+C*S79F) in a 3.8:1 proportion (12.5 to 200 ParC fmol). Enzymes 9 
were incubated with k-DNA (0.4 µg). (C) Relaxation activity of topo IV and its ParCS79F 10 
mutant reconstituted with wtParE, recParC or recParE+recParC in a 3.8:1 proportion (0.3 to 2.5 11 
ParC pmol). Enzymes were incubated with 50 ng of supercoiled plasmid pBR322. 12 
FIG. 3. Mutant topoisomerases showed lower ciprofloxacin-promoted DNA cleavage activities 13 
than wild-type enzyme. (A) Ciprofloxacin-promoted DNA cleavage of gyrase. Plasmid pBR322 14 
DNA (0.4 µg) was incubated with different amounts of reconstituted gyrase (71 to 1140 GyrA 15 
fmol). (B) Ciprofloxacin-promoted DNA cleavage with different amounts of reconstituted topo 16 
IV (lanes E+C) and its ParCS79F mutant (lanes E+CS79F), using 125 to 1000 ParC fmol. (C) 17 
Ciprofloxacin-promoted DNA cleavage by topo IV with recParC (lanes E+C*S79F) or recParE + 18 
recParC (lanes E*+C*S79F). 19 
FIG. 4. Supercoiling levels correlate with bacterial fitness. (A) Distribution of pLS1 topoisomers 20 
of the indicated isogenic strains after two-dimensional agarose gel electrophoresis run in the 21 
presence of 1 and 2 µg/ml chloroquine in the first and second dimensions, respectively. An empty 22 
 31 
arrowhead indicates the most abundant topoisomer. Supercoiling density () values are indicated 1 
below the image of one characteristic gel of each strain as average  SD, number of 2 
determinations (B) Correlation between supercoiling density and fitness at 12 h of growth in 3 
competition with R6. A black square indicates those strains carrying the GyrAE85K change. 4 
5 
 32 
TABLE 1. Oligonucleotides used in this work 1 
Oligonucleotide
a

















 F, forward; R, reverse. The 5´ends of some of the primers contained a sequence including a SphI 3 
restriction site, which is underlined. Bases not present in the R6 strain sequence are lowercased. 4 
5 Con formato: Inglés (Estados Unidos)
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TABLE 2. Enzymatic activities of type II DNA topoisomerases 1 
Subunit purified from strain:  Gyrase specific activity
a
 Topo IV specific activity
 a
 











  R6 R6    8.6 3.7    
  T14 R6  4.3 (2.0) 1.0 (3.7)    
R6 R6      21.2 1.4 3.8 
T1 R6      10.6 (2.0) 0.9 (1.5) 1.2 (3.2) 
T14 R6        6.5 (3.3) 0.9 (1.5) 1.4 (2.7) 
T14 T14        8.3 (2.5) 0.7 (2.0) 1.1 (3.4) 
 2 
a
 Activities are in units/ mg   10
4
, numbers in parentheses are the fold-decrease in activity with 3 
respect to the R6 enzyme. 4 
b
 One unit defined as the amount of enzyme required to convert 50% of 0.4 g of relaxed 5 
pBR322 to the supercoiled form in 1 h at 37ºC.  6 
c
 One unit defined as the amount of enzyme required to linearize 20% of 0.4 µg of CCC pBR322 7 
in 30 min at 37ºC. 8 
d
 One unit defined as the amount of enzyme required to decatenate 50% of 0.4 g of kDNA in 1 h 9 
at 37ºC 10 
e
 One unit defined as the amount of enzyme required to convert 50% of 50 ng of CCC pBR322 to 11 
the OC form in 1 h at 37ºC. 12 
f
 One unit defined as the amount of enzyme required to linearize 50% of 0.4 µg of CCC pBR322 13 
kDNA in 30 min at 37ºC. 14 
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
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